Hyderabad March 29, 2011, Natco Pharma’s (V C Nannapaneni, Chairman & MD) a nti-cancer drug, NRC-AN-019, has received ‘Orphan Drug’ designation from the US Food and Drug Administration (USFDA) for three indications — glioma (brain tumour), pancreatic cancer and chronic myelogenous leukemia. “It is for the first time that an Indian company’s drug is designated as orphan drug by the USFDA for three indications, ” Natco said in a statement today. Orphan drug designation is given by the USFDA for rare diseases that affect less than 200,000 patients in the USA. Since the market for drugs intended to treat rare diseases is small, the USFDA extends special incentives to companies involved in the discovery and development of such drugs. The incentives, according to the Hyderabad-based company, include a seven-year marketing exclusivity, specific tax credits and waiver of prescription drug user fee, which is about $1.5 million per indication. Special grants and benefits to defray the costs ...
visit www.kammavelugu.org for more information and History of Kamma caste, kammavar, కమ్మ, కమ్మ వారు, కమ్మ నాయుడు, Kamma Naidu, Naidoo community people across the Globe